Home/Pipeline/PRX019

PRX019

Alzheimer’s Disease

Not Specified (Preclinical/Discovery)Active (Wholly-owned)

Key Facts

Indication

Alzheimer’s Disease

Phase

Not Specified (Preclinical/Discovery)

Status

Active (Wholly-owned)

Company

Prothena

About Prothena

Prothena is a publicly traded biotech firm with a scientific legacy tracing back to Athena Neurosciences (founded 1986), focusing on the biology of misfolded proteins. It has built a diverse pipeline of investigational therapies, including partnered programs with Roche (prasinezumab for Parkinson's) and Bristol Myers Squibb (PRX005). The company's strategy integrates internal discovery with strategic collaborations to advance transformative medicines for devastating neurological and amyloid disorders.

View full company profile

Therapeutic Areas

Neurodegenerative Diseases Rare Diseases Amyloidosis

Other Alzheimer’s Disease Drugs

Drug	Company	Phase	Status
BMS-986446 (PRX005)	Prothena	Phase 1	Active (Partnered with Bristol Myers Squibb)
Telomir-1	Telomir Pharmaceuticals	Pre-clinical	Active
Laromestrocel (Lomecel-B™)	Longeveron	Phase 2	Active